Condition

Stage IV Lung Cancer AJCC v8

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 153 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials153

Recruiting44

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung CancerNCT07322341 · 2026-10-01

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving PembrolizumabNCT07619599 · 2026-09-14

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationNCT07012031 · 2026-06-17

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT StudyNCT07405086 · 2026-06-08

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialNCT07288034 · 2026-04-08

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung CancerNCT07017829 · 2026-04-01

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)NCT06616584 · 2025-05-22

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung CancerNCT06910761 · 2025-05-05

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyNCT06731270 · 2025-04-09

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerNCT06287775 · 2025-04-08

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialNCT06500481 · 2025-03-04

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung CancerNCT06518057 · 2025-03-03

Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung CancerNCT06743308 · 2024-12-16

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung CancerNCT06660407 · 2024-11-14

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)NCT06031688 · 2024-08-08

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerNCT06495125 · 2024-07-31

Gilteritinib for the Treatment of ALK NSCLCNCT06225427 · 2024-07-25

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialNCT06096844 · 2024-07-19

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung CancerNCT06249282 · 2024-04-24

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer CachexiaNCT06073431 · 2023-12-04

A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung CancerNCT06122064 · 2023-11-20

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerNCT05501665 · 2023-05-09

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · 2023-05-05

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung CancerNCT05746325 · 2023-04-07

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung CancerNCT05570825 · 2023-04-06

Understanding New Cachexia Subtypes Through Observational Epidemiological ResearchNCT07776353 · 2023-04-05

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung CancerNCT05242965 · 2023-03-24

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsNCT05733000 · 2023-03-08

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerNCT05234307 · 2022-11-21

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerNCT05493566 · 2022-11-01

Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung CancerNCT05244239 · 2022-07-27

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerNCT05098210 · 2022-06-09

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsNCT05269381 · 2022-03-31

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung CancerNCT04919382 · 2022-01-26

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung CancerNCT04780568 · 2022-01-18

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerNCT04762199 · 2021-02-24

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With CancerNCT03819296 · 2021-02-21

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid TumorsNCT04771520 · 2021-01-20

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung CancerNCT04151940 · 2019-09-26

Insomnia in Patients With Metastatic Lung CancerNCT06472804 · 2019-06-19

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their CaregiversNCT03948100 · 2018-12-20

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During SurgeryNCT03582124 · 2018-07-19

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer TypesNCT06075524 · 2015-06-15

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialNCT07576725 · 2026-12-01

NOT_YET_RECRUITING

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerNCT07543172 · 2026-10-15

NOT_YET_RECRUITING

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to BonesNCT06982222 · 2026-10-01

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung CancerNCT06816979 · 2026-09-15

NOT_YET_RECRUITING

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung CancerNCT06943664 · 2026-08-15

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)NCT07393555 · 2026-08-07

NOT_YET_RECRUITING

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung CancerNCT05840770 · 2025-04-15

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerNCT06616623 · 2024-12-31

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainNCT06500455 · 2024-12-12

ACTIVE_NOT_RECRUITING

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung CarcinomaNCT06014827 · 2024-10-09

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNCT06067776 · 2024-01-01

NOT_YET_RECRUITING

An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung CancerNCT06315296 · 2023-12-13

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung CancerNCT05935774 · 2023-12-01

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT TrialNCT05161533 · 2023-10-19

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint InhibitorsNCT05967533 · 2023-06-02

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung CancerNCT05498389 · 2023-06-01

Common interventions

Leading sponsors

M.D. Anderson Cancer Center 28 National Cancer Institute (NCI) 24 SWOG Cancer Research Network 13 City of Hope Medical Center 12 Mayo Clinic 11 Ohio State University Comprehensive Cancer Center 9 Emory University 7 University of Washington 7 Roswell Park Cancer Institute 5 Dwight Owen 4 NRG Oncology 4 Fred Hutchinson Cancer Center 3 OHSU Knight Cancer Institute 3 Jonsson Comprehensive Cancer Center 2 Rutgers, The State University of New Jersey 2

Trial status mix

ACTIVE_NOT_RECRUITING50

RECRUITING44

COMPLETED23

TERMINATED15

WITHDRAWN11

NOT_YET_RECRUITING5

SUSPENDED4

UNKNOWN1

Phase mix

PHASE271

PHASE155

NA22

PHASE313

EARLY_PHASE13

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.